Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer

Sponsor:

COG

Sponsor Study ID:

ALTE2131

CTO #:

104254

NCT Number:

NCT06513962

Phase:

III

Protocol Type:

Prevention

Age Group:

Both

Disease Sites:

Anus; Bladder; Bones and Joints; Brain and Nervous System; Cervix Uteri; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Hodgkin Lymphoma; Kaposi's Sarcoma; Kidney; Larynx; Leukemia, other; Lip, Oral Cavity and Pharynx; Liver; Lung; Lymphoid Leukemia; Melanoma, Skin; Multiple Myeloma; Mycosis Fungoides; Myeloid and Monocytic Leukemia; Non-Hodgkin Lymphoma; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid

Study Objectives:

I. Determine the feasibility of conducting a cross network, multi-site, randomized clinical trial of triptorelin among newly diagnosed adolescent and young adult (AYA) female cancer patients age < 40 years (exclusive of breast cancer). II. Measure ovarian reserve via anti-Mullerian hormone (AMH) at 2-years post completion of alkylating agent-containing chemotherapy among randomized patients.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)